Biological Activity
BL-AD008 is an AMPK/ZIPK-directed activator investigated in cervical-cancer apoptosis research. Approximately 50% growth inhibition was reported for this condition; it is not presented as a fitted multi-point IC50.
In Vitro
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Cervical-cancer response | HeLa cells; BL-AD008 600 nM for 24 h. [1] | Approximately 50% growth inhibition was reported for this condition; it is not presented as a fitted multi-point IC50. |
| Apoptotic signaling | HeLa/C4I cellular experiments. [1] | AMPK/ZIPK-associated signaling was linked to mitochondrial and death-receptor apoptotic responses. |
In Vivo
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Xenograft exposure | Female BALB/c nude mice with HeLa xenografts; 10, 20 or 40 mg/kg intraperitoneally daily for 10 days. [1], Methods | Tumor growth, body weight and tissue endpoints were assessed across three dose arms. |
| Tumor markers | Xenograft tissue Ki-67 and TUNEL analyses. [1] | Treatment reduced proliferation-associated staining and increased apoptotic readouts. These short-term observations are not a complete toxicity assessment. |
Interpretation
The reported dual-target model does not establish identical potency or exposure requirements for both kinases.
